TRAVERE THERAPEUTICS INC (TVTX) Stock Price, Forecast & Analysis
USA - NASDAQ:TVTX - US89422G1076 - Common Stock
TVTX Key Statistics, Chart & Performance
The current stock price of TVTX is 35.06 USD. In the past month the price increased by 23.19%. In the past year, price increased by 91.25%.
TVTX Latest News, Press Relases and Analysis
TVTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.68 | 412.08B | ||
| AMGN | AMGEN INC | 15.46 | 182.04B | ||
| GILD | GILEAD SCIENCES INC | 15.25 | 155.01B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.35 | 112.85B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.47 | 73.81B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 901.02 | 60.23B | ||
| INSM | INSMED INC | N/A | 41.36B | ||
| NTRA | NATERA INC | N/A | 28.01B | ||
| BIIB | BIOGEN INC | 10.02 | 24.59B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.72 | 21.15B | ||
| INCY | INCYTE CORP | 16.59 | 20.80B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 34.93 | 14.48B |
Related stock screener links
About TVTX
Company Profile
Travere Therapeutics, Inc. is a biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 385 full-time employees. The company went IPO on 2003-07-23. The firm is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. FILSPARI is an oral, once-daily, non-immunosuppressive medication that directly targets glomerular injury in the kidney. Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (FSGS). The Company’s Pegtibatinase is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU), which is a rare metabolic disorder. Its commercial products, Thiola and Thiola EC, are for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
Company Info
TRAVERE THERAPEUTICS INC
3611 Valley Centre Dr, Suite 300
San Diego CALIFORNIA 92130 US
CEO: Eric M. Dube
Employees: 385
Phone: 18889697879
TRAVERE THERAPEUTICS INC / TVTX FAQ
What does TRAVERE THERAPEUTICS INC do?
Travere Therapeutics, Inc. is a biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 385 full-time employees. The company went IPO on 2003-07-23. The firm is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. FILSPARI is an oral, once-daily, non-immunosuppressive medication that directly targets glomerular injury in the kidney. Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (FSGS). The Company’s Pegtibatinase is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU), which is a rare metabolic disorder. Its commercial products, Thiola and Thiola EC, are for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
What is the stock price of TRAVERE THERAPEUTICS INC today?
The current stock price of TVTX is 35.06 USD. The price increased by 3.45% in the last trading session.
Does TRAVERE THERAPEUTICS INC pay dividends?
TVTX does not pay a dividend.
How is the ChartMill rating for TRAVERE THERAPEUTICS INC?
TVTX has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the analyst forecast for TVTX stock?
21 analysts have analysed TVTX and the average price target is 36.41 USD. This implies a price increase of 3.84% is expected in the next year compared to the current price of 35.06.
Can you provide the PE ratio for TVTX stock?
TRAVERE THERAPEUTICS INC (TVTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.06).
What is the outstanding short interest for TRAVERE THERAPEUTICS INC?
The outstanding short interest for TRAVERE THERAPEUTICS INC (TVTX) is 14.42% of its float.
TVTX Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to TVTX. When comparing the yearly performance of all stocks, TVTX is one of the better performing stocks in the market, outperforming 96.1% of all stocks.
TVTX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to TVTX. TVTX has a bad profitability rating. Also its financial health evaluation is rather negative.
TVTX Financial Highlights
Over the last trailing twelve months TVTX reported a non-GAAP Earnings per Share(EPS) of -1.06. The EPS increased by 75.91% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -16.44% | ||
| ROE | -120.36% | ||
| Debt/Equity | 4.23 |
TVTX Forecast & Estimates
21 analysts have analysed TVTX and the average price target is 36.41 USD. This implies a price increase of 3.84% is expected in the next year compared to the current price of 35.06.
For the next year, analysts expect an EPS growth of 77.25% and a revenue growth 105.69% for TVTX